Back to results
US 2015/0083127 A1Published application
Aggregate particles
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsMichiel Mary Van Oort, John N. Hong
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsMichiel Mary Van Oort, John N. Hong
Estimating the term…
The present invention relates to aggregate particles comprising nanoparticulate drug particles. In particular, the present invention is directed to aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide and optionally vilanterol trifenatate and/or fluticasone furoate. Aggregate particles of the present invention may further comprise nanoparticulate excipient particles and one or more binders. The invention also relates to powder compositions suitable for inhalation that comprise said aggregate particles, processes of producing said aggregate particles, and use of said powder compositions in the treatment of respiratory diseases, such as asthma and COPD.
-58. (canceled)
Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide and vilanterol trifenatate, wherein the aggregate particles have a mass median aerodynamic diameter of less than about 100 μm, and further wherein the nanoparticulate drug particles have an effective average particle size of less than about 1000 nm.
The use of magnesium stearate in aggregate particles which have a mass median aerodynamic diameter of less than about 100 μm, wherein the aggregate particles comprise nanoparticulate drug particles of one or more pharmaceutically active ingredients which have an effective average particle size of less than about 1000 nm, to improve the robustness of the aggregate particles.
Dependencies are inferred from the claim text.